Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Patent
1985-09-30
1990-08-07
Hazel, Blondel
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
424 854, A61K 3766
Patent
active
049466747
ABSTRACT:
This invention relates to the treatment of rheumatic diseases. More particularly, this invention relates to processes and compositions for treating rheumatic diseases by administering to a patient a pharmaceutically effect amount of gamma interferon.
REFERENCES:
patent: 4460574 (1984-07-01), Yabrov
patent: 4480032 (1984-10-01), Yabrov
patent: 4483849 (1984-11-01), Carter et al.
patent: 4606685 (1984-07-01), Vilcek et al.
patent: 4681930 (1987-07-01), Kung et al.
patent: 4727138 (1988-02-01), Goeddel et al.
Chemical Abstracts, vol. 102, Abstract No. 843945, 1985.
Chemical Abstracts, vol. 103, Abstract No. 109975t, 1985.
I. F. Barinskii et al., "Successful Therapy of Autoimmune Disease in NZB/W Mice with Interferon", Chemical Abstracts, 100, abstract 172939d, (1984).
R. C. Butler and D. H. Goddara, "Controversy in the Treatment of Rheumatoid Arthritis": Lancet, Aug. 4, 1984, pp. 278-279, (1984).
M. Degre et al., "Immune Interferon in Serum and Synovial Fluid in Rheumatoid Arthritis and Related Disorders", Ann. Rheum. Dis., 42, pp. 672-676, (1983).
E. G. Engleman et al., "Treatment of NZB/NZW F1 Hybrid Mice with Mycobacterium bovis Strain . . . ", Arthritis Rheum., 24, pp. 1396-1402, (1981).
I. Gresser, "Can Interferon Induce Disease?", INF 4 1982, I. Gresser, ed., Academic Press, pp. 95-127, (Gresser II).
J. J. Hooks et al., "Immune Interferon in the Circulation of Patients with Autoimmune Disease", New Eng. J. Med., 301, pp. 5-8, (1979), (Hooks et al. I).
J. J. Hooks et al., "The Role of Interferon in Immediate Hypersensitivity and Autoimmune Disease", Ann. N.Y. Acad. Sci., 350, pp. 21-32, (1980), (Hooks et al. II).
A. Kajander et al., "Interferon Treatment of Rheumatoid Arthritis", Lancet, May 5, 1979, pp. 984-985, (1979).
T. O. Rosenbach et al., "Interferon Triggers Experimental Synovitis and May Potentiate Auto-Immune Disease in Humans", Clin. Rheum., 3, pp. 361-364, (1984).
G. Sonnenfeld et al., "Time and Dosage Dependencies of Immunoenhancement by Murine Type II Interferon Preparations", Cell Immunol., 40, pp. 285-293, (1978).
M. L. Stephenson et al., "Immune Interferon Inhibits Collagen Synthesis by Rheumatoid Synovial Cells . . . ", Chemical Abstracts, 102, abstract 130150j, (1985).
M. L. Stephenson et al., "Immune Interferon Inhibits Collagen Synthesis by Rheumatoid Synovial Cells . . . ", FEBS Lett., 180, pp. 43-50, (1985).
T. H. Bacon et al, "The Use of Interferon in Diseases of Uncertain Aetiology", In Interferon, vol. 4, N. B. Finter, ed., Elseiver, Amsterdam, pp. 226, 227 and 229, (1985).
D. Boraschi et al., "Interferon-Gamma Reduces Macrophage-Suppressive Activity by Inhibiting Prostaglandin E.sub.2 Release and Inducing Interleukin 1 Production", J. Immunol., 133, pp. 764-768, (1984).
T. C. Cesario, "The Clinical Implications of Human Interferon", Medical Clinics of North America, 67, pp. 1147-1162, (1983).
"Topical Formulations Containing Interferons for Treatment of Lupus Erythematosus", Chemical Abstracts, 103, citation No. 103:92861c, (1985).
"Genetech, Biogen Report New Advances in Anti-Cancer, AIDS", Chemical Marketing Reporter, Jun. 11, 1984, pp. 5, 26, (1984).
R. C. Chin et al., "The Absence of Gamma-Interferon (Gamma-IFN) and the Presence of High Levels of Inflammatory Mediators . . . ", Fed. Proc., 42, Abstract 3838, p. 947, (1983).
B. Combe et al., "Interleukin-2 in Rheumatoid Arthritis: Production of and Response to Interleukin-2 . . . ", Arthritis Rheum., Abstract, 27 (Suppl.), p. S55, (1984), [Combe I].
B. Combe et al., "Regulation of Natural Killer Cell Activity by Macrophages in the Rheumatoid Joint and Peripheral Blood", J. Immunol., 133, pp. 709--713, (1984), [Combe II].
W. R. Fleischmann et al., "Demonstration of Potentiation of The Antiviral and Antitumor Actions of Interferon", Meth. Enzymol., 79, pp. 432-440, (1981).
F. Hasler et al., "Analysis of the Defects Responsible for the Impaired Regulation of Epstein-Barr Virus-Induced B Cell . . . ", J. Exp. Med., 157, pp. 173-188, (1983).
F. Hasler et al., "Analysis of the Defects Responsible for the Impaired Regulation of EBV-Induced B Cell . . . ", J. Immunol., 131, pp. 768-772, (1983).
K. Itoh et al., "Depressed Natural Killer Activity in Rheumatoid Arthritis and Its in vitro Augmentation . . . ", The Ryumachi, 21, (Suppl.), pp. 69-74, (1981).
S. A. Jiminez et al., "Selective Inhibition of Human Diploid Fibroblast Collagen Synthesis by Interferons", J. Clin. Invest., 74, pp. 1112-1116, (1984).
M. Lipinski et al., "Natural Killer and Killer Cell Activities in Pateints with Primary Immunodeficiencies or Defects in Immune Interferon Production", Eur. J. Immunol., 10, pp. 246-249, (1980).
I. Mecs et al., "The Anti-Inflammatory Effect of Human Interferons in Mice", Contr. Oncol., 20, pp. 221-223, (1984).
O. J. Mellbye et al., "Immunological Research and the Rheumatic Patient: Status and Perspectives in Some Major Areas", Scand. J. Rheumatol., Supplement 53, pp. 64-84, (1984).
A. G. Mowat, "Slow-Acting Antirheumatic Drugs", S. Afr. Med. J., 61, pp. 346-348, (1982).
"Inferferon Nomenclature", Nature, 286, p. 110, (1980), 13th Arztliche . . . , Nov. 25 und 26, 1983; Programmheft S. 8, 9, 22, (1983).
K. T. Pearlstein et al., "Purified Human Interleukin-2 Enhances Induction of Immune Interferon", Cell. Immunol., 80, pp. 1-9, (1983).
C. M. Pearson et al., "Workshop IV. Aetiopathogenic Factors in Reiter's Syndrome", Ann. Rheum. Dis., 38, Supplement, pp. 102-110, (1977), [Pearson I].
C. M. Pearson et al., "Adjuvant Arthritis: Immune Responses and Effects of Tilorone or Interferon . . . ", Perspect. Inflammation Proc. Int. Meet. 3rd, pp. 131-146, (1979), [Pearson II].
S. Pestka et al., "Definition and Classification of the Interferons", Meth. Enzymol., 78, pp. 3-14, (1981).
O. T. Preble et al., "Systemic Lupus Erythematosus: Presence in Human Serum of an Unusual Acid-Lbile Leukocyte Interferon", Science, 216, pp. 429-431, (1982).
G. H. Reem et al., "Interleukin 2 Regulates Expression of Its Receptor and Synthesis of Gamma Interferon by Human T Lymphocytes", Science, 225, pp. 429-430, (1984).
Scand. J. Rheumatol., Supplement 49, p. 59, (1983).
M. L. Thoman et al., "Deficiency in Suppressor T Cell Activity in Aged Animals", J. Exp. Med., 157, pp. 2184-2189, (1983).
D. Wallach, "Regulation of Susceptibility to Natural Killer Cells' Cytotoxicity and Regulation of HLA Synthesis . . . ", J. Interferon Res., 2, pp. 329-338, (1982), [Wallach I].
D. Wallach, "Interferon-Induced Resistance to the Killing by NK Cells: A Preferential Effect of IFN--", Cell. Immunol., 75, pp. 390-395, (1983), [Wallach II].
Link Franz
Obert Hans-Joachim
von Eichborn Johann-Friedrich
Bioferon Biochemische Substanzen GmbH & Co.
Haley, Jr. James F.
Hazel Blondel
Marks Andrew S.
Yankwich Leon R.
LandOfFree
Process for treatment of rheumatic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for treatment of rheumatic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for treatment of rheumatic diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-959721